MENU
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
  • About Us
  • Blog
  • Series
  • Category
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
  1. Home
  2. PROTAC

PROTAC– tag –

  • Oncology Drug

    New Series|Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 6 Final: BRD4 and CDK Crosstalk — The Future of Super-Enhancer Targeting)

    From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. In this final installment, ...
    2025-11-15
  • Pharma & Biotech News

    Series “Reading 2025 Layoffs”: Reshaping by Disease Areas: From Oncology to Neuroscience (Part 2)

    Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 2 Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 2 What you will learn Key TakeawaysPurposeOncology (Solid & Hematologic)Neuroscie...
    2025-09-28
  • Drug Discovery News
    AI Drug Discovery

    BPI Technology: A Site-Specific Strategy That Could Reshape Targeted Protein Degradation

    BPI Technology Advances Targeted Protein Degradation — A Site-Specific Strategy to Accelerate Drug Discovery Introduction Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, offering a means to ...
    2025-07-09
1
MorningMorning|管理人

創薬の最前線に20年以上。基礎研究から新薬開発、そして投資の側まで――投資家の視点も持ちながら、がん領域を軸に日米欧で歩いてきました。最先端のがん治療・創薬・AI創薬・バイオ投資を、正確に、面白く、毎日お届けします。

▶ もっと詳しく(プロフィール)

▶ X:@MorningGlorySci

コメント・ご質問、お待ちしています。

MorningMorning|Author

20+ years at the frontline of drug discovery — from basic research to development to the investor's side. Oncology-focused, across Japan, the US, and Europe. Cutting-edge cancer therapy, drug discovery, AI drug development, and biotech investment — accurate and engaging, every day.

▶ More (Profile)

▶ X: @MorningGlorySci

Comments & questions welcome.

  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語

© Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~.

  • Menu
  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語